Sialyltransferase 7A Double Nickase Plasmid (h): sc-406723-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Sialyltransferase 7A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Sialyltransferase 7A Double Nickase Plasmid (h) and Sialyltransferase 7A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ST6GALNAC1. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sialyltransferase 7A Double Nickase Plasmid (h) | sc-406723-NIC | 20 µg | $410.00 | |||
Sialyltransferase 7A Double Nickase Plasmid (h2) | sc-406723-NIC-2 | 20 µg | $410.00 |
ST6GALNAC1 encodes sialyltransferase 7A, a Golgi-resident glycosyltransferase that transfers sialic acid to GalNAc-containing O-glycans to generate α2,6-sialylated structures such as sialyl-Tn. By shaping mucin-type O-glycosylation, it influences glycoprotein trafficking, cell–cell and cell–matrix interactions, and lectin-mediated signaling within the sialylation and glycoconjugate biosynthesis pathways. Altered ST6GALNAC1 activity is associated with aberrant glycan patterns observed in epithelial biology and immune recognition. Dysregulated O-glycan sialylation has been linked to changes in adhesion, invasion-related phenotypes, and tumor-associated glycoepitopes in multiple cancer contexts, supporting its relevance in glycomics-focused disease mechanism studies.
Sialyltransferase 7A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ST6GALNAC1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ST6GALNAC1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ST6GALNAC1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ST6GALNAC1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.